OraSure Technologies, Inc. (NASDAQ:OSUR) has received an average recommendation of “Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $15.81.

Several research analysts recently commented on the company. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group restated a “buy” rating and issued a $20.00 price objective on shares of OraSure Technologies in a research note on Tuesday, September 12th. Finally, Canaccord Genuity restated a “buy” rating and issued a $22.00 price objective on shares of OraSure Technologies in a research note on Tuesday, September 19th.

In related news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the purchase, the director now directly owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Douglas A. Michels sold 25,000 shares of the firm’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $22.55, for a total value of $563,750.00. Following the transaction, the chief executive officer now owns 743,058 shares in the company, valued at approximately $16,755,957.90. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. First Mercantile Trust Co. acquired a new stake in shares of OraSure Technologies in the 2nd quarter valued at $104,000. Pinebridge Investments L.P. acquired a new stake in shares of OraSure Technologies during the 2nd quarter valued at $131,000. Victory Capital Management Inc. boosted its holdings in shares of OraSure Technologies by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 1,360 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in shares of OraSure Technologies during the 3rd quarter valued at $186,000. Finally, Profund Advisors LLC boosted its holdings in shares of OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 293 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

OraSure Technologies (NASDAQ OSUR) traded up $0.14 during mid-day trading on Thursday, hitting $17.60. The stock had a trading volume of 928,761 shares, compared to its average volume of 890,695. The firm has a market capitalization of $1,060.00, a PE ratio of 33.46, a P/E/G ratio of 3.34 and a beta of 1.28. OraSure Technologies has a 52 week low of $8.39 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The firm had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. During the same period in the prior year, the firm posted $0.11 earnings per share. The business’s quarterly revenue was up 31.0% compared to the same quarter last year. equities analysts predict that OraSure Technologies will post 0.42 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “OraSure Technologies, Inc. (OSUR) Given Average Recommendation of “Buy” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/orasure-technologies-inc-osur-given-average-recommendation-of-buy-by-analysts.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Analyst Recommendations for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.